Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD libvatrep - TRPV1 antagonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04630158 SAHARA (CSAF312B12201) Chronic ocular surface pain Phase 2 150 Change in mean pain severity Visual Analog Scale Placebo Comparator: SAF312 Placebo. Randomized to a 1:1:1 topical eye drops, twice daily Experimental: SAF312 dose 1. Randomized to a 1:1:1 topical eye drops, twice daily Experimental: SAF312 dose 2. Randomized to a 1:1:1 topical eye drops, twice daily Subjects with CICP persisting at least for 4 months after refractive surgery and chronicity confirmed during the observational period. Target Patients Read-out Milesstone(s) Publication 2023 2023 100 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation